News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lundbeck Inc. (LUN.CO) Announces Positive Results for Brintellix™ (Vortioxetine) in Adult Patients With Major Depression and Inadequate Response to SSRI or SNRI Therapy


4/8/2013 11:37:26 AM

Valby, Denmark, 8 April 2013 - H. Lundbeck A/S (Lundbeck) today announced positive results for the REVIVE study, a double-blind randomized study of Brintellix™ (vortioxetine) versus agomelatine in adults with major depression (MDD) who changed antidepressant treatment after an inadequate response to SSRI or SNRI treatment. In this study, the objective was to compare the efficacy and tolerability of flexible dose treatment with Brintellix (10-20mg/day) versus agomelatine (25-50 mg/day) in this challenging MDD patient population. The study was conducted in Europe and one of the newest antidepressants agomelatine was chosen as a comparator because of its different mode of action from conventional SSRI/SNRI therapies.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES